Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL [Phase 1]
Phase 1 trial evaluating acalabrutinib with anti-CD20 therapy and venetoclax in relapsed/refractory or untreated chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL [Phase 2]
An update on a Phase II trial evaluating MOR00208 in combination with lenalidomide for relapsed/refractory or untreated older patients with …
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax [Phase 1, Phase 2]
A Phase 1/2 trial evaluating pirtobrutinib (LOXO-305) as consolidation to eradicate minimal residual disease in chronic lymphocytic leukemia…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas [Phase 1]
Phase 1 clinical trial update for ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select …
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study of BAFF CAR-T cells (LMY-920) for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma is curren…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). [Phase 2]
Phase II clinical trial update for a time-limited combination therapy (pirtobrutinib, venetoclax, obinutuzumab) in recurrent Chronic Lymphoc…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
Phase 2 clinical trial update assessing changes in disease activity and adverse events when oral venetoclax is combined with intravenous obi…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients [Phase 1]
Phase 1 study assessing rituximab plus high-dose methylprednisolone debulking before venetoclax in patients with chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
Post-marketing surveillance update for Calquence (acalabrutinib) in relapsed or refractory chronic lymphocytic leukemia, including small lym…
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial update assessing lenalidomide in combination with a vaccine therapy for patients with early-stage asymptomatic chroni…
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) [Phase 1]
Phase 1 study update for CD19 CAR-allogeneic NKT therapy (ANCHOR) in relapsed or refractory B-cell malignancies; the trial is currently acti…
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study [Phase 2]
Phase 2 DIRECT trial evaluating daratumumab with ibrutinib for relapsed or refractory chronic lymphocytic leukemia was terminated, with resu…
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL [Phase 1]
Phase I study of ONO-4685 as monotherapy to evaluate tolerability and safety in relapsed or refractory T cell lymphoma and chronic lymphocyt…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL [Phase 1, Phase 2]
A clinical trial is evaluating APG2575 as both a single agent and in combination therapy for relapsed/refractory chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: A Study Of The Selective PKC-β Inhibitor MS- 553 [Phase 1, Phase 2]
A Phase 1/2 study of the selective PKC-β inhibitor MS-553 in chronic lymphocytic leukemia, small lymphocytic lymphoma, and aggressive lympho…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]
Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing pirtobrutinib (LOXO-305) against investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab) in…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL [Phase 2]
Phase 2 trial evaluating the AU2 combination (acalabrutinib, umbralisib, and ublituximab) in relapsed and untreated chronic lymphocytic leuk…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 trial evaluating SD-101 (TLR9 agonist) and BMS-986178 (anti-OX40 antibody) with radiation therapy for low-grade B-cell non-Hodgkin l…